StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report sent to investors on Tuesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
TTNP opened at $5.07 on Tuesday. The business has a fifty day simple moving average of $5.89 and a 200 day simple moving average of $6.60. Titan Pharmaceuticals has a 1 year low of $4.24 and a 1 year high of $11.40.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) earnings per share for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Stories
- Five stocks we like better than Titan Pharmaceuticals
- Insider Trades May Not Tell You What You Think
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- Transportation Stocks Investing
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.